Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.
Sponsor: Pfizer
Summary
The purpose of this study is to look at the safety of BEVACIZUMAB BS \[Pfizer\] when it was used to colorectal cancer patients in real-world clinical setting in Japan. The study population includes individuals who have a diagnosis of colorectal cancer and have been treated with Bevacizumab-Pfizer Biosimilar or Avastin between 1 December 2019 and 30 November 2024. Data source is the Medical Data Vision (MDV) database - a hospital-based claims database in Japan.
Official title: BEVACIZUMAB BS INTRAVENOUS INFUSION 100MG, 400MG [PFIZER] POST-MARKETING DATABASE STUDY
Key Details
Gender
All
Age Range
15 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1000
Start Date
2026-04-20
Completion Date
2026-05-31
Last Updated
2026-05-28
Healthy Volunteers
No
Conditions
Interventions
Bevacizumab-Pfizer Biosimilar
As provided in real world practice
Avastin
As provided in real world practice
Locations (1)
Pfizer
Tokyo, Japan